During the last session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares were 0.71 million, with the beta value of the company hitting 1.50. At the
In the last trading session, 1.08 million shares of the Monte Rosa Therapeutics Inc (NASDAQ:GLUE) were traded, and its beta was 1.53. Most recently the
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 0.72 million during the last session, with the company’s beta value hitting 1.53. At the close
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 1.13 million during the last session, with the company’s beta value hitting 1.56. At the close
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 3.05 million during the last session, with the company’s beta value hitting 1.50. At the close
During the last session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares were 0.59 million, with the beta value of the company hitting 1.48. At the
In the last trading session, 2.13 million shares of the Monte Rosa Therapeutics Inc (NASDAQ:GLUE) were traded, and its beta was 1.29. Most recently the
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 2.47 million during the last session, with the company’s beta value hitting 1.33. At the close
In last trading session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw 0.54 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share
During the last session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares were 0.82 million, with the beta value of the company hitting 1.40. At the
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
